The stock of Unity Biotechnology Inc (UBX) has gone up by 18.33% for the week, with a 15.76% rise in the past month and a -13.06% drop in the past quarter. The volatility ratio for the week is 11.53%, and the volatility levels for the past 30 days are 8.18% for UBX. The simple moving average for the past 20 days is 14.36% for UBX’s stock, with a -23.78% simple moving average for the past 200 days.

Is It Worth Investing in Unity Biotechnology Inc (NASDAQ: UBX) Right Now?

and a 36-month beta value of 0.49. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

The average price predicted for Unity Biotechnology Inc (UBX) by analysts is $7.33, which is $5.2 above the current market price. The public float for UBX is 13.19M, and at present, short sellers hold a 4.92% of that float. On November 20, 2023, the average trading volume of UBX was 52.55K shares.

UBX) stock’s latest price update

Unity Biotechnology Inc (NASDAQ: UBX) has experienced a rise in its stock price by 17.68 compared to its previous closing price of 1.81. However, the company has seen a gain of 18.33% in its stock price over the last five trading days. InvestorPlace reported 2023-10-17 that Longevity stocks have started to come on many investors’ radars. These companies come with the promise of stable returns over the long run as human life continues to stretch further ahead.

Analysts’ Opinion of UBX

Many brokerage firms have already submitted their reports for UBX stocks, with Wedbush repeating the rating for UBX by listing it as a “Outperform.” The predicted price for UBX in the upcoming period, according to Wedbush is $4 based on the research report published on November 16, 2023 of the current year 2023.

UBX Trading at 3.11% from the 50-Day Moving Average

After a stumble in the market that brought UBX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.76% of loss for the given period.

Volatility was left at 8.18%, however, over the last 30 days, the volatility rate increased by 11.53%, as shares surge +14.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.46% lower at present.

During the last 5 trading sessions, UBX rose by +18.33%, which changed the moving average for the period of 200-days by -55.63% in comparison to the 20-day moving average, which settled at $1.88. In addition, Unity Biotechnology Inc saw -22.26% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at UBX starting from Ghosh Anirvan, who sale 589 shares at the price of $1.83 back on Nov 02. After this action, Ghosh Anirvan now owns 80,609 shares of Unity Biotechnology Inc, valued at $1,078 using the latest closing price.

Ghosh Anirvan, the Chief Executive Officer of Unity Biotechnology Inc, sale 1,024 shares at $1.90 during a trade that took place back on Oct 30, which means that Ghosh Anirvan is holding 81,198 shares at $1,946 based on the most recent closing price.

Stock Fundamentals for UBX

Current profitability levels for the company are sitting at:

• -23589.83 for the present operating margin
• -823.73 for the gross margin

The net margin for Unity Biotechnology Inc stands at -25392.80. The total capital return value is set at -47.63, while invested capital returns managed to touch -56.32. Equity return is now at value -91.54, with -51.08 for asset returns.

Based on Unity Biotechnology Inc (UBX), the company’s capital structure generated 75.48 points at debt to equity in total, while total debt to capital is 43.01. Total debt to assets is 40.58, with long-term debt to equity ratio resting at 56.67. Finally, the long-term debt to capital ratio is 32.29.

The liquidity ratio also appears to be rather interesting for investors as it stands at 4.92.

Conclusion

To sum up, Unity Biotechnology Inc (UBX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.